Key result
Serotonin antagonists show varying effects on carcinoid flushing without clear quantitative benefit.
Answers are grounded in this paper and cite their sources.
Investigates the influence of serotonin antagonists on flushing attacks in carcinoid syndrome and vascular responses in healthy individuals, highlighting therapeutic potential.
The pathogenesis of flushing attacks in patients with malignant carcinoid tumors is attributed to the direct pharmacologic effect of excessive amounts of circulating serotonin. It was hoped that potent serotonin antagonists might relieve symptoms of the carcinoid syndrome in the inoperable patient. The nature of flushing attacks was studied in carcinoid patients and the influence thereon of 3 serotonin antagonists, a benzyl analog of serotonin, bromo-lysergic acid diethylamide, and chlorpromazine. The systemic, subjective, and vascular effects of these antagonists in normal subjects were also investigated.
No takes yet. Share an insight, caveat, or question.
Schneckloth et al. (1957) studied Malignant carcinoid tumors / carcinoid syndrome. Serotonin antagonists (benzyl analog of serotonin, bromo-lysergic acid diethylamide, and chlorpromazine) vs. Normal subjects was evaluated on Flushing attacks and systemic, subjective, and vascular effects. Three serotonin antagonists (benzyl analog of serotonin, bromo-lysergic acid diethylamide, and chlorpromazine) were evaluated for effects on carcinoid flushing, with no quantitative results in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: